Albuterol HFA-BOI — Competitive Intelligence Brief

Albuterol HFA-BOI (Albuterol HFA-BOI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-2 adrenergic agonist (short-acting). Area: Respiratory.

phase 2 Beta-2 adrenergic agonist (short-acting) Beta-2 adrenergic receptor (ADRB2) Respiratory Small molecule

Target snapshot

Albuterol HFA-BOI (Albuterol HFA-BOI) — Teva Branded Pharmaceutical Products R&D, Inc.. Albuterol is a beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Albuterol HFA-BOI TARGET	Albuterol HFA-BOI	Teva Branded Pharmaceutical Products R&D, Inc.	phase 2	Beta-2 adrenergic agonist (short-acting)	Beta-2 adrenergic receptor (ADRB2)
Terbutaline Infusion	Terbutaline Infusion	Muhammad Aamir Latif	marketed	Beta-2 adrenergic agonist (short-acting)	Beta-2 adrenergic receptor (ADRB2)
Levalbuterol (R albuterol)	Levalbuterol (R albuterol)	Children's Hospital of Philadelphia	marketed	Beta-2 adrenergic agonist (short-acting)	Beta-2 adrenergic receptor
Albuterol-HFA-MDI	Albuterol-HFA-MDI	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Beta-2 adrenergic agonist (short-acting)	Beta-2 adrenergic receptor
Primatene Mist	Primatene Mist	Amphastar Pharmaceuticals, Inc.	marketed	Beta-2 adrenergic agonist (short-acting)	Beta-2 adrenergic receptor
Nebulized Salbutamol	Nebulized Salbutamol	Hospital General Naval de Alta Especialidad - Escuela Medico Naval	marketed	Beta-2 adrenergic agonist (short-acting)	Beta-2 adrenergic receptor
salbutamol pressurized metered dose inhaler	salbutamol pressurized metered dose inhaler	University of Saskatchewan	marketed	Beta-2 adrenergic agonist (short-acting)	Beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-2 adrenergic agonist (short-acting) class)

1. Teva Branded Pharmaceutical Products R&D, Inc. · 3 drugs in this class
2. Sumitomo Pharma America, Inc. · 2 drugs in this class
3. GlaxoSmithKline · 1 drug in this class
4. Hospital General Naval de Alta Especialidad - Escuela Medico Naval · 1 drug in this class
5. Muhammad Aamir Latif · 1 drug in this class
6. NYU Langone Health · 1 drug in this class
7. Organon and Co · 1 drug in this class
8. Sanofi · 1 drug in this class
9. Amphastar Pharmaceuticals, Inc. · 1 drug in this class
10. University of Saskatchewan · 1 drug in this class